We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
-$122M
Cap. Flow
-$69.5M
Cap. Flow %
-4.44%
Top 10 Hldgs %
64.55%
Holding
66
New
15
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$46.2M
2
ISRG icon
Intuitive Surgical
ISRG
+$36.9M
3
BIIB icon
Biogen
BIIB
+$36.7M
4
MRK icon
Merck
MRK
+$25.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$23.6M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$95.2M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$74.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$57.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$45.3M
5
AZN icon
AstraZeneca
AZN
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$13.9B
$16.1M 1.03%
+831,243
New +$14.5M
VIR icon
27
Vir Biotechnology
VIR
$1.47B
$15.3M 0.98%
+657,559
New +$16.8M
CLDX icon
28
Celldex Therapeutics
CLDX
$2.77B
$15.1M 0.97%
+419,397
New +$18.1M
RXDX
29
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$13.3M 0.85%
123,842
-52,703
-30% -$6.07M
CYTK icon
30
Cytokinetics
CYTK
$11B
$12.5M 0.8%
353,796
-155,134
-30% -$6.33M
CTIC
31
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$11.7M 0.75%
2,794,542
-1,811,985
-39% -$9.41M
YMAB
32
DELISTED
Y-mAbs Therapeutics
YMAB
$11M 0.7%
2,194,278
– –
AGEN
33
Agenus
AGEN
$249M
$9.74M 0.62%
326,460
+179,008
+121% +$7.56M
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.28M 0.53%
+1,200,389
New +$7.53M
GRTX
35
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$7.89M 0.5%
3,083,712
– –
KURA icon
36
Kura Oncology
KURA
$922M
$7.54M 0.48%
616,169
+22,608
+4% +$282K
AXSM icon
37
Axsome Therapeutics
AXSM
$12.4B
$7.46M 0.48%
+120,896
New +$7.94M
IDYA icon
38
IDEAYA Biosciences
IDYA
$3.41B
$6.22M 0.4%
453,149
-21,381
-5% -$356K
NCNA
39
NuCana
NCNA
$5.37M
$5.38M 0.34%
1,120
– –
RVMD icon
40
Revolution Medicines
RVMD
$40.2B
$3.98M 0.25%
+183,838
New +$4.53M
NXTC icon
41
NextCure
NXTC
$17.3M
$3.95M 0.25%
222,655
– –
IMGN
42
CALL
DELISTED
Immunogen Inc
IMGN
$3.84M 0.25%
+1,000,000
New +$4.26M
BOLT icon
43
Bolt Biotherapeutics
BOLT
$7.36M
$3.83M 0.24%
137,722
– –
IMGN
44
DELISTED
Immunogen Inc
IMGN
$3.55M 0.23%
924,532
-761,622
-45% -$3.25M
KROS icon
45
Keros Therapeutics
KROS
$199M
$3.29M 0.21%
+77,100
New +$3.89M
NVCR icon
46
CALL
NovoCure
NVCR
$2.04B
$3.01M 0.19%
+50,000
New +$4M
BLUE
47
DELISTED
bluebird bio
BLUE
$2.14M 0.14%
+33,641
New +$3.84M
PDSB icon
48
PDS Biotechnology
PDSB
$38.1M
$877K 0.06%
142,635
– –
FUSN
49
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$441K 0.03%
117,099
– –
SYBX
50
DELISTED
Synlogic
SYBX
$363K 0.02%
38,331
– –
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2023 Portfolio in Review

As of Q1 2023, Sofinnova Investments held 66 positions worth $1.56B, down 7.2% from $1.69B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $69.5M in Q1 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Sanofi, an estimated $95.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $47.1M.

  • Sofinnova Investments's largest Q1 2023 buy was Eli Lilly: 137,100 shares worth $47.1M.
  • Sofinnova Investments added most to Merck in Q1 2023, an estimated $25.7M increase.
  • Sofinnova Investments's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $57.4M.
  • Sofinnova Investments fully exited Sanofi in Q1 2023, selling an estimated $95.2M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.56B portfolio in Q1 2023.
  • Sofinnova Investments opened 15 new positions and closed 14 in Q1 2023.
  • Sofinnova Investments's portfolio value fell 7.2% quarter-over-quarter to $1.56B.

Based on Sofinnova Investments's 13F filing for Q1 2023, filed 11 May 2023.